Jeff Yass’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.31M | Buy |
27,829
+8,834
| +47% | +$1.57M | ﹤0.01% | 4188 |
|
|
2026
Q1 | $3.28M | Sell |
18,995
-4,712
| -20% | -$874K | ﹤0.01% | 5093 |
|
|
2025
Q4 | $4.73M | Sell |
23,707
-9,491
| -29% | -$1.72M | ﹤0.01% | 4113 |
|
|
2025
Q3 | $5.19M | Buy |
33,198
+800
| +2% | +$127K | ﹤0.01% | 4025 |
|
|
2025
Q2 | $4.92M | Sell |
32,398
-5,981
| -16% | -$798K | ﹤0.01% | 4006 |
|
|
2025
Q1 | $5.78M | Sell |
38,379
-16,325
| -30% | -$2.74M | ﹤0.01% | 3374 |
|
|
2024
Q4 | $10.1M | Buy |
54,704
+21,997
| +67% | +$4.24M | ﹤0.01% | 2653 |
|
|
2024
Q3 | $6.44M | Buy |
32,707
+16,062
| +96% | +$3.34M | ﹤0.01% | 3188 |
|
|
2024
Q2 | $3.44M | Sell |
16,645
-400
| -2% | -$90.6K | ﹤0.01% | 4071 |
|
|
2024
Q1 | $4.62M | Buy |
17,045
+584
| +4% | +$139K | ﹤0.01% | 3757 |
|
|
2023
Q4 | $3.89M | Sell |
16,461
-43,528
| -73% | -$8.56M | ﹤0.01% | 4145 |
|
|
2023
Q3 | $11.8M | Buy |
59,989
+21,416
| +56% | +$4.4M | ﹤0.01% | 2353 |
|
|
2023
Q2 | $8.11M | Buy |
38,573
+12,804
| +50% | +$2.55M | ﹤0.01% | 2791 |
|
|
2023
Q1 | $5.2M | Buy |
25,769
+6,555
| +34% | +$1.49M | ﹤0.01% | 3411 |
|
|
2022
Q4 | $4.19M | Buy |
19,214
+18,132
| +1,676% | +$3.96M | ﹤0.01% | 3507 |
|
|
2022
Q3 | $213K | Sell |
1,082
-42,613
| -98% | -$9.2M | ﹤0.01% | 10682 |
|
|
2022
Q2 | $9.35M | Buy |
43,695
+17,016
| +64% | +$4.16M | ﹤0.01% | 2287 |
|
|
2022
Q1 | $7.58M | Sell |
26,679
-8,564
| -24% | -$2.64M | ﹤0.01% | 2942 |
|
|
2021
Q4 | $13.3M | Buy |
35,243
+13,231
| +60% | +$5.14M | ﹤0.01% | 2330 |
|
|
2021
Q3 | $9.08M | Sell |
22,012
-96
| -0.4% | -$39.9K | ﹤0.01% | 3010 |
|
|
2021
Q2 | $8.18M | Buy |
22,108
+9,658
| +78% | +$3.22M | ﹤0.01% | 3204 |
|
|
2021
Q1 | $3.61M | Buy |
12,450
+9,566
| +332% | +$2.66M | ﹤0.01% | 4559 |
|
|
2020
Q4 | $721K | Sell |
2,884
-868
| -23% | -$207K | ﹤0.01% | 7467 |
|
|
2020
Q3 | $850K | Buy |
3,752
+1,215
| +48% | +$252K | ﹤0.01% | 6513 |
|
|
2020
Q2 | $442K | Sell |
2,537
-19,950
| -89% | -$3.18M | ﹤0.01% | 7628 |
|
|
2020
Q1 | $2.84M | Buy |
22,487
+18,465
| +459% | +$2.77M | ﹤0.01% | 3382 |
|
|
2019
Q4 | $614K | Buy |
+4,022
| New | +$557K | ﹤0.01% | 6531 |
|
|
2019
Q3 | – | Sell |
-14,591
| Closed | -$1.96M | – | 10235 |
|
|
2019
Q2 | $2.07M | Buy |
+14,591
| New | +$1.98M | ﹤0.01% | 4104 |
|
|
2017
Q3 | – | Sell |
-6,497
| Closed | -$667K | – | 8896 |
|
|
2017
Q2 | $657K | Buy |
+6,497
| New | +$598K | ﹤0.01% | 6111 |
|
|
2016
Q2 | – | Sell |
-12,280
| Closed | -$1.01M | – | 8619 |
|
|
2016
Q1 | $933K | Buy |
12,280
+8,647
| +238% | +$640K | ﹤0.01% | 5228 |
|
|
2015
Q4 | $292K | Sell |
3,633
-1,277
| -26% | -$92.1K | ﹤0.01% | 7740 |
|
|
2015
Q3 | $312K | Sell |
4,910
-71,089
| -94% | -$5.1M | ﹤0.01% | 7976 |
|
|
2015
Q2 | $5.35M | Sell |
75,999
-24,405
| -24% | -$1.81M | ﹤0.01% | 2813 |
|
|
2015
Q1 | $7.96M | Sell |
100,404
-3,491
| -3% | -$258K | ﹤0.01% | 2125 |
|
|
2014
Q4 | $6.61M | Buy |
103,895
+29,295
| +39% | +$1.84M | ﹤0.01% | 2490 |
|
|
2014
Q3 | $4.46M | Sell |
74,600
-8,796
| -11% | -$503K | ﹤0.01% | 3193 |
|
|
2014
Q2 | $4.46M | Buy |
+83,396
| New | +$4.58M | ﹤0.01% | 3271 |
|
|
2014
Q1 | – | Sell |
-20,500
| Closed | -$1.19M | – | 8941 |
|
|
2013
Q4 | $1.09M | Sell |
20,500
-10,609
| -34% | -$533K | ﹤0.01% | 5356 |
|
|
2013
Q3 | $1.44M | Buy |
31,109
+10,609
| +52% | +$487K | ﹤0.01% | 4682 |
|
|
2013
Q2 | $841K | Buy |
+20,500
| New | +$878K | ﹤0.01% | 5283 |
|
Other funds holding CRL
AI
Jeff Yass's CRL Position: Q2 2026 in Review
Jeff Yass increased its Charles River Laboratories (CRL) stake by 47% in Q2 2026, buying an estimated $1.57M and bringing the position to 27,829 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4188.
Jeff Yass first reported a position in CRL in Q2 2013 and has held it in 40 quarters since. The position peaked at $13.3M in Q4 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Jeff Yass held 27,829 shares of Charles River Laboratories worth $6.31M as of Q2 2026.
- Jeff Yass bought 8,834 Charles River Laboratories shares in Q2 2026, an estimated $1.57M.
- Charles River Laboratories made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4188 holding.
- Jeff Yass first reported a position in Charles River Laboratories in Q2 2013 and has held it in 40 quarters since.
- Jeff Yass's Charles River Laboratories position peaked at $13.3M in Q4 2021.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.